ホーム > 市場調査レポート > 医薬品

感染症呼吸器

市場調査レポート

商品コード

1085749

市中感染細菌性肺炎（CABP）治療薬の世界市場：薬剤クラス別、剤形別、投与経路別、流通チャネル別、地域別 - 規模、シェア、展望、機会分析、（2022年～2028年）

Community-acquired Bacterial Pneumonia Treatment Drugs Market, by Drug Class, by Dose Form, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: 2022年05月28日 | 発行: Coherent Market Insights

| ページ情報: 英文 188 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,500 705,420円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,097,320円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,567,600円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界の市中感染細菌性肺炎（CABP）治療薬市場では、主要企業間の無機戦略が各社の市場シェアを上昇させています。しかし、薬剤の抗生物質に対する耐性が、市場成長の妨げになっています。

当レポートでは、世界の市中感染細菌性肺炎（CABP）治療薬市場について調査分析し、市場促進要因と抑制要因、市場機会、COVID-19の影響、薬剤クラス・剤形・投与経路・流通チャネル・地域別の市場分析、競合情勢などを提供しています。

ヒートマップ分析
市場シェア分析
- Nabriva Therapeutics
- Paratek Pharmaceuticals, Inc.
- Melinta Therapeutics, Inc.
- Allergan plc
- Bayer AG
- Lupin Pharmaceuticals, Inc.
- Mylan NV
- Sanofi SA
- Pfizer Inc.
- Dainippon Sumitomo Pharma
- Takeda Pharmaceutical Company Limited
- Basilea Pharmaceutica International AG
- Analyst Views

第11章セクション

Product Code: CMI4269

Community-acquired bacterial pneumonia (CABP) is most common acute respiratory illnesses among various infections triggering sepsis. Microbiologically, bacteria are common agents causing pneumonia, with Streptococcus pneumoniae being the most common cause worldwide. CABP is the most common infectious causes of illness and hospitalization, especially in the geriatric population. For instance, according to the National Center for Biotechnology Information (NCBI), in March 2020, the incidence of community-acquired pneumonia (CAP) in the U.S. is more than 5 million per year.

Market Dynamics

Inorganic strategies amongst key players are strengthening the companies' market share in global community-acquired bacterial pneumonia (CABP) treatment drugs market. For instance, in 2017, Avir Pharma Inc. (Avir), an affiliate of the Laboratoire RIVA Group, entered into a Canadian distribution and license agreement with Basilea Pharmaceutica Ltd. for its antifungal Cresemba (isavuconazole) and antibiotic Zevtera (ceftobiprole). Avir plans to apply for a marketing authorization for isavuconazole in Canada. Zevtera is already approved by Health Canada for the treatment of adult patients with hospital-acquired pneumonia (HAP) and for the treatment of community-acquired pneumonia (CAP) and will be purchasing product from Basilea and will commercialize in Canada.

However, antibiotic resistance in drugs is hampering the market growth. For instance, according to an article published in November 2021 in the National Center for Biotechnology Information (NCBI), in pneumococcal pneumonia, beta-lactam as monotherapy may not be optimal therapy even if bacteria remain susceptible to the beta-lactam. Therefore, antibiotic resistance are expected to restrain the global community-acquired bacterial pneumonia (CABP) treatment drugs market.

Key features of the study:

This report provides in-depth analysis of the global community-acquired bacterial pneumonia (CABP) treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global community-acquired bacterial pneumonia (CABP) treatment drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global community-acquired bacterial pneumonia (CABP) treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global community-acquired bacterial pneumonia (CABP) treatment drugs market.

Detailed Segmentation:

Global Community-Acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class:
- Pleuromutilin Antibiotic
- Cephalosporin
- Glycylcycline
- Oxazolidinone
- Ketolide
- Others
Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Dose Form:
- Solution
- Tablet
Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Route of Administration:
- Oral
- Intravenous
Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region:
- North America
  - By Drug Class:
  - Pleuromutilin Antibiotic
  - Cephalosporin
  - Glycylcycline
  - Oxazolidinone
  - Ketolide
  - Others
  - By Dose Form:
  - Solution
  - Tablet
  - By Route of Administration
  - Oral
  - Parental
  - Topical
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - U.S.
  - Canada
- Latin America
  - By Drug Class:
  - Pleuromutilin Antibiotic
  - Cephalosporin
  - Glycylcycline
  - Oxazolidinone
  - Ketolide
  - Others
  - By Dose Form:
  - Solution
  - Tablet
  - By Route of Administration
  - Oral
  - Parental
  - Topical
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - By Drug Class:
  - Pleuromutilin Antibiotic
  - Cephalosporin
  - Glycylcycline
  - Oxazolidinone
  - Ketolide
  - Others
  - By Dose Form:
  - Solution
  - Tablet
  - By Route of Administration
  - Oral
  - Parental
  - Topical
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - By Drug Class:
  - Pleuromutilin Antibiotic
  - Cephalosporin
  - Glycylcycline
  - Oxazolidinone
  - Ketolide
  - Others
  - By Dose Form:
  - Solution
  - Tablet
  - By Route of Administration
  - Oral
  - Parental
  - Topical
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - By Drug Class:
  - Pleuromutilin Antibiotic
  - Cephalosporin
  - Glycylcycline
  - Oxazolidinone
  - Ketolide
  - Others
  - By Dose Form:
  - Solution
  - Tablet
  - By Route of Administration
  - Oral
  - Parental
  - Topical
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - By Drug Class:
  - Pleuromutilin Antibiotic
  - Cephalosporin
  - Glycylcycline
  - Oxazolidinone
  - Ketolide
  - Others
  - By Dose Form:
  - Solution
  - Tablet
  - By Route of Administration
  - Oral
  - Parental
  - Topical
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
- Nabriva Therapeutics*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Highlights
  - Market Strategies
- Paratek Pharmaceuticals, Inc.
- Melinta Therapeutics, Inc.
- Allergan plc
- Bayer AG
- Lupin Pharmaceuticals, Inc.
- Mylan N.V.
- Sanofi S.A.
- Pfizer Inc.
- Dainippon Sumitomo Pharma
- Takeda Pharmaceutical Company Limited
- Basilea Pharmaceutica International AG

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Dose Form
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Pipeline Analysis
Reimbursement Scenario
Epidemiology
Pest Analysis
Regulatory Scenario
New Product Launches
Collaborations and Agreements
Market Trends

4. Global Community-Acquired Bacterial Pneumonia (CABP) Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Market Scenario
Impact of COVID-19 Market on the Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Products

5. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Pleuromutilin Antibiotic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Glycylcycline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Oxazolidinone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Ketolide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Dose Form, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Solution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Tablet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Route of Administration, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

8. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

9. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
North America
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
Latin America
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Dose Form, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa

10. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- Nabriva Therapeutics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Paratek Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Melinta Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Allergan plc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Lupin Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Mylan N.V.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Dainippon Sumitomo Pharma
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Basilea Pharmaceutica International AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views

11. Section

References
Research Methodology
About us and Sales Contact

ライセンス / 価格

PDF (Single User License)

USD 4,500 705,420円

PDF (Multi User License)

USD 7,000 1,097,320円

PDF (Enterprise User License)

USD 10,000 1,567,600円

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

お電話でのお問い合わせ

044-952-0102

( 土日・祝日を除く )

細菌性肺炎

市中感染細菌性肺炎（CABP）治療薬の世界市場：薬剤クラス別、剤形別、投与経路別、流通チャネル別、地域別 - 規模、シェア、展望、機会分析、（2022年～2028年）

Community-acquired Bacterial Pneumonia Treatment Drugs Market, by Drug Class, by Dose Form, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章調査目的・前提条件

第2章市場の範囲

第3章市場力学・規制・動向分析

第4章世界の市中感染細菌性肺炎（CABP）治療薬市場：COVID-19流行の影響

第5章世界の市中感染細菌性肺炎（CABP）治療薬市場：薬剤クラス別（2017年～2028年）

第6章世界の市中感染細菌性肺炎（CABP）治療薬市場：剤形別（2017年～2028年）

第7章世界の市中感染細菌性肺炎（CABP）治療薬市場：投与経路別（2017年～2028年）

第8章世界の市中感染細菌性肺炎（CABP）治療薬市場：流通チャネル別（2017年～2028年）

第9章世界の市中感染細菌性肺炎（CABP）治療薬市場：地域別（2017年～2028年）

第10章競合情勢

第11章セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Community-Acquired Bacterial Pneumonia (CABP) Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class, 2017 - 2028, (US$ Mn)

6. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Dose Form, 2017 - 2028, (US$ Mn)

7. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Route of Administration, 2017 - 2028, (US$ Mn)

8. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

9. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region, 2017 - 2028, (US$ Mn)

10. Competitive Landscape

11. Section

市中感染細菌性肺炎（CABP）治療薬の世界市場：薬剤クラス別、剤形別、投与経路別、流通チャネル別、地域別 - 規模、シェア、展望、機会分析、（2022年～2028年）

Community-acquired Bacterial Pneumonia Treatment Drugs Market, by Drug Class, by Dose Form, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章 調査目的・前提条件

第2章 市場の範囲

第3章 市場力学・規制・動向分析

第4章 世界の市中感染細菌性肺炎（CABP）治療薬市場：COVID-19流行の影響

第5章 世界の市中感染細菌性肺炎（CABP）治療薬市場：薬剤クラス別（2017年～2028年）

第6章 世界の市中感染細菌性肺炎（CABP）治療薬市場：剤形別（2017年～2028年）

第7章 世界の市中感染細菌性肺炎（CABP）治療薬市場：投与経路別（2017年～2028年）

第8章 世界の市中感染細菌性肺炎（CABP）治療薬市場：流通チャネル別（2017年～2028年）

第9章 世界の市中感染細菌性肺炎（CABP）治療薬市場：地域別（2017年～2028年）

第10章 競合情勢

第11章 セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Community-Acquired Bacterial Pneumonia (CABP) Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class, 2017 - 2028, (US$ Mn)

6. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Dose Form, 2017 - 2028, (US$ Mn)

7. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Route of Administration, 2017 - 2028, (US$ Mn)

8. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

9. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region, 2017 - 2028, (US$ Mn)

10. Competitive Landscape

11. Section

第1章調査目的・前提条件

第2章市場の範囲

第3章市場力学・規制・動向分析

第4章世界の市中感染細菌性肺炎（CABP）治療薬市場：COVID-19流行の影響

第5章世界の市中感染細菌性肺炎（CABP）治療薬市場：薬剤クラス別（2017年～2028年）

第6章世界の市中感染細菌性肺炎（CABP）治療薬市場：剤形別（2017年～2028年）

第7章世界の市中感染細菌性肺炎（CABP）治療薬市場：投与経路別（2017年～2028年）

第8章世界の市中感染細菌性肺炎（CABP）治療薬市場：流通チャネル別（2017年～2028年）

第9章世界の市中感染細菌性肺炎（CABP）治療薬市場：地域別（2017年～2028年）

第10章競合情勢

第11章セクション